Biomarkers of body iron stores and risk of developing type 2 diabetes

Swapnil Rajpathak, Judith Wylie-Rosett, M. J. Gunter, Abdissa Negassa, G. C. Kabat, Thomas E. Rohan, Jill P. Crandall

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Aim: Iron may contribute to the pathogenesis of type 2 diabetes mellitus (DM) by inducing oxidative stress and interfering with insulin secretion. Elevated ferritin levels are associated with increased DM risk among healthy individuals. However, it is yet unknown if ferritin predicts DM incidence among high-risk individuals with impaired glucose tolerance (IGT). Furthermore, the association between soluble transferrin receptors (sTfR), a novel marker of iron status, and DM risk has not yet been prospectively investigated in these individuals. We conducted this study to evaluate the association between baseline levels of ferritin and sTfR and the risk of developing DM among overweight and obese individuals at high risk of DM. Methods: This nested case-control study (280 cases and 280 matched controls) was conducted within the placebo arm of the Diabetes Prevention Program, is a clinical trial conducted among overweight/obese individuals with IGT. Ferritin and sTfR levels were measured by immunoturbidimetric assays. Incident DM was ascertained by annual 75-g oral glucose tolerance test and semi-annual fasting glucose. Results: Compared with controls, cases had higher sTfR levels (3.50 ± 0.07 vs. 3.30 ± 0.06 mg/l; p = 0.03), but ferritin levels were not statistically different. The multivariable odds ratios (OR) and 95% confidence intervals (95% CI) for DM incidence comparing highest with the lowest quartiles of sTfR was 2.26 (1.37-4.01) (p-trend: 0.008). Conclusions: Modestly elevated sTfR levels are associated with increased DM risk among overweight and obese individuals with IGT. Future studies should evaluate factors determining sTfR levels and examine if interventions that lower body iron stores reduce DM incidence.

Original languageEnglish (US)
Pages (from-to)474-479
Number of pages6
JournalDiabetes, Obesity and Metabolism
Volume11
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Transferrin Receptors
Type 2 Diabetes Mellitus
Diabetes Mellitus
Iron
Biomarkers
Ferritins
Glucose Intolerance
Incidence
Glucose Tolerance Test
Case-Control Studies
Fasting
Oxidative Stress
Odds Ratio
Placebos
Clinical Trials
Confidence Intervals
Insulin
Glucose

Keywords

  • Ferritin
  • Transferrin receptors
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Biomarkers of body iron stores and risk of developing type 2 diabetes. / Rajpathak, Swapnil; Wylie-Rosett, Judith; Gunter, M. J.; Negassa, Abdissa; Kabat, G. C.; Rohan, Thomas E.; Crandall, Jill P.

In: Diabetes, Obesity and Metabolism, Vol. 11, No. 5, 2009, p. 474-479.

Research output: Contribution to journalArticle

@article{c37fabb391c44a309e8f617bc64d11eb,
title = "Biomarkers of body iron stores and risk of developing type 2 diabetes",
abstract = "Aim: Iron may contribute to the pathogenesis of type 2 diabetes mellitus (DM) by inducing oxidative stress and interfering with insulin secretion. Elevated ferritin levels are associated with increased DM risk among healthy individuals. However, it is yet unknown if ferritin predicts DM incidence among high-risk individuals with impaired glucose tolerance (IGT). Furthermore, the association between soluble transferrin receptors (sTfR), a novel marker of iron status, and DM risk has not yet been prospectively investigated in these individuals. We conducted this study to evaluate the association between baseline levels of ferritin and sTfR and the risk of developing DM among overweight and obese individuals at high risk of DM. Methods: This nested case-control study (280 cases and 280 matched controls) was conducted within the placebo arm of the Diabetes Prevention Program, is a clinical trial conducted among overweight/obese individuals with IGT. Ferritin and sTfR levels were measured by immunoturbidimetric assays. Incident DM was ascertained by annual 75-g oral glucose tolerance test and semi-annual fasting glucose. Results: Compared with controls, cases had higher sTfR levels (3.50 ± 0.07 vs. 3.30 ± 0.06 mg/l; p = 0.03), but ferritin levels were not statistically different. The multivariable odds ratios (OR) and 95{\%} confidence intervals (95{\%} CI) for DM incidence comparing highest with the lowest quartiles of sTfR was 2.26 (1.37-4.01) (p-trend: 0.008). Conclusions: Modestly elevated sTfR levels are associated with increased DM risk among overweight and obese individuals with IGT. Future studies should evaluate factors determining sTfR levels and examine if interventions that lower body iron stores reduce DM incidence.",
keywords = "Ferritin, Transferrin receptors, Type 2 diabetes",
author = "Swapnil Rajpathak and Judith Wylie-Rosett and Gunter, {M. J.} and Abdissa Negassa and Kabat, {G. C.} and Rohan, {Thomas E.} and Crandall, {Jill P.}",
year = "2009",
doi = "10.1111/j.1463-1326.2008.00985.x",
language = "English (US)",
volume = "11",
pages = "474--479",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Biomarkers of body iron stores and risk of developing type 2 diabetes

AU - Rajpathak, Swapnil

AU - Wylie-Rosett, Judith

AU - Gunter, M. J.

AU - Negassa, Abdissa

AU - Kabat, G. C.

AU - Rohan, Thomas E.

AU - Crandall, Jill P.

PY - 2009

Y1 - 2009

N2 - Aim: Iron may contribute to the pathogenesis of type 2 diabetes mellitus (DM) by inducing oxidative stress and interfering with insulin secretion. Elevated ferritin levels are associated with increased DM risk among healthy individuals. However, it is yet unknown if ferritin predicts DM incidence among high-risk individuals with impaired glucose tolerance (IGT). Furthermore, the association between soluble transferrin receptors (sTfR), a novel marker of iron status, and DM risk has not yet been prospectively investigated in these individuals. We conducted this study to evaluate the association between baseline levels of ferritin and sTfR and the risk of developing DM among overweight and obese individuals at high risk of DM. Methods: This nested case-control study (280 cases and 280 matched controls) was conducted within the placebo arm of the Diabetes Prevention Program, is a clinical trial conducted among overweight/obese individuals with IGT. Ferritin and sTfR levels were measured by immunoturbidimetric assays. Incident DM was ascertained by annual 75-g oral glucose tolerance test and semi-annual fasting glucose. Results: Compared with controls, cases had higher sTfR levels (3.50 ± 0.07 vs. 3.30 ± 0.06 mg/l; p = 0.03), but ferritin levels were not statistically different. The multivariable odds ratios (OR) and 95% confidence intervals (95% CI) for DM incidence comparing highest with the lowest quartiles of sTfR was 2.26 (1.37-4.01) (p-trend: 0.008). Conclusions: Modestly elevated sTfR levels are associated with increased DM risk among overweight and obese individuals with IGT. Future studies should evaluate factors determining sTfR levels and examine if interventions that lower body iron stores reduce DM incidence.

AB - Aim: Iron may contribute to the pathogenesis of type 2 diabetes mellitus (DM) by inducing oxidative stress and interfering with insulin secretion. Elevated ferritin levels are associated with increased DM risk among healthy individuals. However, it is yet unknown if ferritin predicts DM incidence among high-risk individuals with impaired glucose tolerance (IGT). Furthermore, the association between soluble transferrin receptors (sTfR), a novel marker of iron status, and DM risk has not yet been prospectively investigated in these individuals. We conducted this study to evaluate the association between baseline levels of ferritin and sTfR and the risk of developing DM among overweight and obese individuals at high risk of DM. Methods: This nested case-control study (280 cases and 280 matched controls) was conducted within the placebo arm of the Diabetes Prevention Program, is a clinical trial conducted among overweight/obese individuals with IGT. Ferritin and sTfR levels were measured by immunoturbidimetric assays. Incident DM was ascertained by annual 75-g oral glucose tolerance test and semi-annual fasting glucose. Results: Compared with controls, cases had higher sTfR levels (3.50 ± 0.07 vs. 3.30 ± 0.06 mg/l; p = 0.03), but ferritin levels were not statistically different. The multivariable odds ratios (OR) and 95% confidence intervals (95% CI) for DM incidence comparing highest with the lowest quartiles of sTfR was 2.26 (1.37-4.01) (p-trend: 0.008). Conclusions: Modestly elevated sTfR levels are associated with increased DM risk among overweight and obese individuals with IGT. Future studies should evaluate factors determining sTfR levels and examine if interventions that lower body iron stores reduce DM incidence.

KW - Ferritin

KW - Transferrin receptors

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84878635879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878635879&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2008.00985.x

DO - 10.1111/j.1463-1326.2008.00985.x

M3 - Article

VL - 11

SP - 474

EP - 479

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 5

ER -